CoChat
Sign Up
Cited by 84

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Role of microRNAs in glioblastoma

Chen, Ming, Medarova, Zdravka, Moore, Anna·2021·Oncotarget
DOI 10.18632/oncotarget.28039PMC PMC8378762
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.28039

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 165

  1. Kleihues, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 11, 97, 10.1007/s00401-007-0243-4 · DOI
  2. Kumar, 2016, MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics, Cancer Med, 5, 1917, 10.1002/cam4.775 · DOI
  3. Barnholtz-Sloan, 2014, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011, Neuro Oncol, 1, iv1, 10.1093/neuonc/nou223 · DOI
  4. Gijtenbeek, 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, 1, 459, 10.1016/S1470-2045(09)70025-7 · DOI
  5. Khasraw, 2020, Management of glioblastoma: State of the art and future directions, CA Cancer J Clin, 7, 299, 10.3322/caac.21613 · DOI
  6. Scott, 2001, The developmental biology of brain tumors, Annu Rev Neurosci, 2, 385, 10.1146/annurev.neuro.24.1.385 · DOI
  7. Parada, 2002, The molecular and genetic basis of neurological tumours, Nat Rev Cancer, 2, 616, 10.1038/nrc866 · DOI
  8. Holland, 2010, Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma, Nat Rev Cancer, 1, 319, 10.1038/nrc2818 · DOI
  9. Liu, 2020, Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma, Cell Stem Cell, 2, 48, 10.1016/j.stem.2019.11.015 · DOI · Paper page
  10. Petrov, 2020, A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity, Cell, 18, 188, 10.1016/j.cell.2019.11.036 · DOI · Paper page
  11. Chang, 2015, Toward precision medicine in glioblastoma: the promise and the challenges, Neuro Oncol, 1, 1051, 10.1093/neuonc/nov031 · DOI
  12. Seelig, 1998, Blood-brain barrier permeation: molecular parameters governing passive diffusion, J Membr Biol, 16, 201, 10.1007/s002329900434 · DOI
  13. Grindstaff, 2008, Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier bybiotinylation, Neuroscience, 15, 423, 10.1016/j.neuroscience.2008.06.015 · DOI
  14. Antohe, 2002, Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey, Microsc Res Tech, 5, 269, 10.1002/jemt.10086 · DOI
  15. Davis, 2003, Pain and the blood-brain barrier: obstacles to drug delivery, Adv Drug Deliv Rev, 5, 987, 10.1016/s0169-409x(03)00100-5 · DOI
  16. Moos, 2012, Brain delivery systems via mechanism independent of receptor-mediated endocytosis and adsorptive-mediated endocytosis, Curr Pharm Biotechnol, 1, 2349, 10.2174/138920112803341842 · DOI
  17. Romero, 1996, Transporting therapeutics across the blood-brain barrier, Mol Med Today, 2, 106, 10.1016/1357-4310(96)88720-x · DOI
  18. Bendayan, 2001, Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations, Pharmacol Rev, 5, 569
  19. Zlokovic, 2018, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat Rev Neurol, 1, 133, 10.1038/nrneurol.2017.188 · DOI · Paper page
  20. Ronaldson, 2014, Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?, Curr Pharm Des, 2, 1422, 10.2174/13816128113199990463 · DOI
  21. Erickson, 2012, Insulin in the brain: there and back again, Pharmacol Ther, 13, 82, 10.1016/j.pharmthera.2012.07.006 · DOI
  22. Pardridge, 1999, Selective expression of the large neutral amino acid transporter at the blood-brain barrier, Proc Natl Acad Sci U S A, 9, 12079, 10.1073/pnas.96.21.12079 · DOI
  23. Luo, 2020, Amino acid transporters: Emerging roles in drug delivery for tumor-targeting therapy, Asian J Pharm Sci, 1, 192, 10.1016/j.ajps.2019.12.002 · DOI
  24. Begley, 2004, ABC transporters and the blood-brain barrier, Curr Pharm Des, 1, 1295, 10.2174/1381612043384844 · DOI
  25. Kim, 2002, Drugs as P-glycoprotein substrates, inhibitors, and inducers, Drug Metab Rev, 3, 47, 10.1081/dmr-120001389 · DOI
  26. Fricker, 2011, The ABC of the blood-brain barrier - regulation of drug efflux pumps, Curr Pharm Des, 1, 2762, 10.2174/138161211797440221 · DOI
  27. Miller, 2010, Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier, Trends Pharmacol Sci, 3, 246, 10.1016/j.tips.2010.03.003 · DOI
  28. Günday Türeli, 2020, Key for crossing the BBB with nanoparticles: the rational design, Beilstein J Nanotechnol, 1, 866, 10.3762/bjnano.11.72 · DOI
  29. Gessler, 2017, Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels, Sci Signal, 1, eaag2476, 10.1126/scisignal.aag2476 · DOI
  30. Freskgård, 2012, Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictiveblood-brain barrier models, PLoS One, 7, e38149, 10.1371/journal.pone.0038149 · DOI
  31. Lakka, 2017, MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review, Crit Rev Oncol Hematol, 12, 22, 10.1016/j.critrevonc.2017.10.003 · DOI
  32. Hannon, 2004, MicroRNAs: small RNAs with a big role in gene regulation, Nat Rev Genet, 5, 522, 10.1038/nrg1379 · DOI · Paper page
  33. Romani, 2017, MicroRNA in Glioblastoma: An Overview, Int J Genomics, 201, 7639084, 10.1155/2017/7639084 · DOI
  34. Jing, 2012, MicroRNA degradation and turnover: regulating the regulators, Wiley Interdiscip Rev RNA, 3, 593, 10.1002/wrna.1114 · DOI
  35. Kabilova, 2018, Nucleotide Modifications Decrease Innate Immune Response Induced by Synthetic Analogs of snRNAs and snoRNAs, Genes (Basel), 9, 531, 10.3390/genes9110531 · DOI
  36. Li, 2019, Biogenesis and function of extracellular miRNAs, ExRNA, 1, 38, 10.1186/s41544-019-0039-4 · DOI
  37. Vyas, 2015, A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery, Drug Deliv, 2, 231, 10.3109/10717544.2014.882469 · DOI
  38. Lu, 2017, RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?, Front Immunol, 8, 331, 10.3389/fimmu.2017.00331 · DOI
  39. Farace, 2005, Extensive modulation of a set of microRNAs in primary glioblastoma, Biochem Biophys Res Commun, 33, 1351, 10.1016/j.bbrc.2005.07.030 · DOI · Paper page
  40. Duroux, 2013, A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion, Mol Neurobiol, 4, 131, 10.1007/s12035-012-8349-7 · DOI
  41. Slack, 2016, OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer, Cancer Res, 7, 3666, 10.1158/0008-5472.CAN-16-0359 · DOI
  42. Fine, 2011, Prediction of Associations between microRNAs and Gene Expression in Glioma Biology, PLoS One, 6, e14681, 10.1371/journal.pone.0014681 · DOI
  43. Wion, 2011, MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes, PLoS One, 6, e20600, 10.1371/journal.pone.0020600 · DOI · Paper page
  44. Ungerechts, 2011, MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism, Mol Ther, 1, 1097, 10.1038/mt.2011.55 · DOI
  45. Liu, 2011, MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression, Chin Med J (Engl), 12, 2616
  46. Luo, 2011, The effect of miR-7 on behavior and global protein expression in glioma cell lines, Electrophoresis, 3, 3612, 10.1002/elps.201100230 · DOI
  47. Purow, 2008, microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma, Cancer Res, 6, 3566, 10.1158/0008-5472.CAN-07-6639 · DOI · Paper page
  48. Li, 2014, MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1, Tumour Biol, 3, 10177, 10.1007/s13277-014-2318-x · DOI
  49. Kuersten, 2014, Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells, PLoS One, 9, e85591, 10.1371/journal.pone.0085591 · DOI
  50. Abounader, 2009, MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes, Cancer Res, 6, 7569, 10.1158/0008-5472.CAN-09-0529 · DOI · Paper page
  51. Phillip Koeffler, 2013, miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme, Oncogene, 3, 1155, 10.1038/onc.2012.132 · DOI
  52. Huang, 2010, MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251, Arch Med Res, 4, 67, 10.1016/j.arcmed.2010.02.007 · DOI
  53. Abounader, 2010, microRNA-34a is tumor suppressive in brain tumors and glioma stem cells, Cell Cycle, 9, 1031, 10.4161/cc.9.6.10987 · DOI
  54. Li, 2011, MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme, Cancer Biol Ther, 1, 477, 10.4161/cbt.12.6.16300 · DOI
  55. Zhao, 2016, MicroRNA-34a inhibits cell proliferation and induces cell apoptosis of glioma cells via targeting of Bcl-2, Mol Med Rep, 1, 432, 10.3892/mmr.2016.5255 · DOI
  56. Shiras, 2014, Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways, FEBS Open Bio, 4, 485, 10.1016/j.fob.2014.05.002 · DOI
  57. Sée, 2014, Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells, PLoS One, 9, e108514, 10.1371/journal.pone.0108514 · DOI
  58. Huse, 2012, miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis, PLoS One, 7, e33844, 10.1371/journal.pone.0033844 · DOI
  59. Penalva, 2011, The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs, RNA Biol, 8, 817, 10.4161/rna.8.5.16041 · DOI
  60. Lawler, 2008, Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal, Cancer Res, 6, 9125, 10.1158/0008-5472.CAN-08-2629 · DOI · Paper page
  61. Peng, 2009, MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a, J Mol Med (Berl), 8, 43, 10.1007/s00109-008-0403-6 · DOI · Paper page
  62. Lukiw, 2010, Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation, J Neurooncol, 9, 297, 10.1007/s11060-009-0077-0 · DOI
  63. He, 2016, miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3, Oncotarget, 7, 78813, 10.18632/oncotarget.12385 · DOI · Paper page
  64. Kosik, 2012, Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases, Oncogene, 3, 1884, 10.1038/onc.2011.380 · DOI · Paper page
  65. Godlewski, 2019, The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma, Nat Commun, 1, 442, 10.1038/s41467-019-08390-z · DOI · Paper page
  66. Jiang, 2012, MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1, PLoS One, 7, e32709, 10.1371/journal.pone.0032709 · DOI
  67. Gerlitz, 2010, Gliomas display a microRNA expression profile reminiscent of neural precursor cells, Neuro Oncol, 1, 422, 10.1093/neuonc/nop061 · DOI
  68. Kohmura, 2009, MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC, Int J Cancer, 12, 1407, 10.1002/ijc.24522 · DOI
  69. Liu, 2011, MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10, Brain Res, 138, 9, 10.1016/j.brainres.2011.03.013 · DOI
  70. Krichevsky, 2011, Human glioma growth is controlled by microRNA-10b, Cancer Res, 7, 3563, 10.1158/0008-5472.CAN-10-3568 · DOI · Paper page
  71. Krichevsky, 2015, MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma, Oncotarget, 6, 3770, 10.18632/oncotarget.3009 · DOI
  72. Abounader, 2013, Oncogenic effects of miR-10b in glioblastoma stem cells, J Neurooncol, 11, 153, 10.1007/s11060-013-1047-0 · DOI
  73. Kosik, 2005, MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells, Cancer Res, 6, 6029, 10.1158/0008-5472.CAN-05-0137 · DOI · Paper page
  74. Shah, 2007, MicroRNA-21 knockdown disrupts glioma growthand displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas, Cancer Res, 6, 8994, 10.1158/0008-5472.CAN-07-1045 · DOI · Paper page
  75. Yu, 2009, MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme, Brain Res, 128, 13, 10.1016/j.brainres.2009.06.053 · DOI
  76. Kang, 2010, MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol, BMC Cancer, 1, 27, 10.1186/1471-2407-10-27 · DOI
  77. Wang, 2010, MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity, Brain Res, 135, 255, 10.1016/j.brainres.2010.07.009 · DOI
  78. Kang, 2010, Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3, Oncol Rep, 2, 195, 10.3892/or_00000846 · DOI
  79. Kang, 2010, Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status, Lab Invest, 9, 144, 10.1038/labinvest.2009.126 · DOI
  80. Shin, 2011, Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas, Oncogene, 3, 2433, 10.1038/onc.2010.620 · DOI · Paper page
  81. Kawamoto, 2011, A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells, Brain Tumor Pathol, 2, 209, 10.1007/s10014-011-0037-1 · DOI
  82. Brocke-Heidrich, 2011, MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4, Oncogene, 3, 2975, 10.1038/onc.2011.15 · DOI
  83. Zheng, 2017, Reduction of miR-21 induces SK-N-SH cell apoptosis and inhibits proliferation via PTEN/PDCD4, Oncol Lett, 1, 4727, 10.3892/ol.2017.6052 · DOI
  84. Mempel, 2016, Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain, Neuro Oncol, 1, 58, 10.1093/neuonc/nov244 · DOI · Paper page
  85. Xue, 2015, MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG, Mol Biol Rep, 4, 721, 10.1007/s11033-014-3820-3 · DOI · Paper page
  86. Pedroso de Lima, 2015, MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma, J Control Release, 20, 31, 10.1016/j.jconrel.2015.04.002 · DOI
  87. Leung, 2012, MicroRNA-21 inhibition enhanceschemosensitivity of temozolomide-resistant glioblastoma cells, Anticancer Res, 3, 2835
  88. Iwamoto, 2012, Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma, J Neurooncol, 10, 391, 10.1007/s11060-012-0906-4 · DOI
  89. Kang, 2015, Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes, Int J Oncol, 4, 1589, 10.3892/ijo.2015.2841 · DOI
  90. Somasundaram, 2010, Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma, Mod Pathol, 2, 1404, 10.1038/modpathol.2010.135 · DOI
  91. Cheng, 2019, MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy, Autophagy, 1, 1100, 10.1080/15548627.2019.1569947 · DOI
  92. Xiong, 2010, Investigation gene and microRNA expression in glioblastoma, BMC Genomics, 1, S16, 10.1186/1471-2164-11-S3-S16 · DOI
  93. Barciszewski, 2015, Comprehensive analysis of microRNA expression profile in malignant glioma tissues, Mol Oncol, 9, 1324, 10.1016/j.molonc.2015.03.007 · DOI · Paper page
  94. Huang, 2012, A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing, OMICS, 1, 690, 10.1089/omi.2012.0069 · DOI
  95. Chen, 2016, MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide, Biol Open, 5, 669, 10.1242/bio.015552 · DOI
  96. Yang, 2011, MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8, Oncogene, 3, 806, 10.1038/onc.2010.465 · DOI
  97. Kang, 2010, MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma, Mol Cancer, 9, 229, 10.1186/1476-4598-9-229 · DOI
  98. Kang, 2012, Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status, Oncol Rep, 2, 854, 10.3892/or.2011.1535 · DOI
  99. Stein, 2008, MicroRNAs 221 and 222 bypass quiescence and compromise cell survival, Cancer Res, 6, 2773, 10.1158/0008-5472.CAN-07-6754 · DOI
  100. Jiang, 2009, Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1and, Int J Oncol, 3, 1653, 10.3892/ijo_00000296 · DOI
  101. Zhang, 2014, miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status, Curr Mol Med, 1, 185, 10.2174/1566524013666131203103147 · DOI
  102. Yan, 2011, Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells, Mol Cancer, 1, 59, 10.1186/1476-4598-10-59 · DOI
  103. Wen, 2011, [Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis], Zhonghua Bing Li Xue Za Zhi, 4, 454
  104. Jiang, 2013, MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity, Neuro Oncol, 1, 413, 10.1093/neuonc/nos296 · DOI
  105. Kang, 2010, MiRNA-451 plays a role as tumor suppressor in human glioma cells, Brain Res, 135, 14, 10.1016/j.brainres.2010.08.074 · DOI
  106. Olson, 2009, AngiomiRs--key regulators of angiogenesis, Curr Opin Genet Dev, 1, 205, 10.1016/j.gde.2009.04.002 · DOI
  107. Reijerkerk, 2012, Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma, FASEB J, 2, 2639, 10.1096/fj.11-202820 · DOI
  108. Krichevsky, 2008, miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells, Cancer Cell, 1, 382, 10.1016/j.ccr.2008.10.005 · DOI
  109. Kulshreshtha, 2014, Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing, BMC Genomics, 1, 686, 10.1186/1471-2164-15-686 · DOI
  110. Yamashita, 2010, miR-195, miR-455-3p and miR-10a() are implicated in acquired temozolomide resistance in glioblastoma multiforme cells, Cancer Lett, 29, 241, 10.1016/j.canlet.2010.04.013 · DOI
  111. Michalek, 2010, MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients, Neoplasma, 5, 264, 10.4149/neo_2010_03_264 · DOI
  112. Yu, 2010, Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance, Med Sci Monit, 1, HY27
  113. Yang, 2012, MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma, PLoS One, 7, e47270, 10.1371/journal.pone.0047270 · DOI
  114. Hodgson, 2008, miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells, BMC Med, 6, 14, 10.1186/1741-7015-6-14 · DOI · Paper page
  115. Abounader, 2009, The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors, J Neurosci, 2, 15161, 10.1523/JNEUROSCI.4966-09.2009 · DOI
  116. Givol, 2008, MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells, Biochem Biophys Res Commun, 37, 86, 10.1016/j.bbrc.2008.08.107 · DOI
  117. Abounader, 2019, MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway, J Neurooncol, 14, 23, 10.1007/s11060-019-03275-z · DOI
  118. Toren, 2013, MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1, Oncotarget, 4, 665, 10.18632/oncotarget.928 · DOI
  119. Chiou, 2012, Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI, Biomaterials, 3, 1462, 10.1016/j.biomaterials.2011.10.071 · DOI
  120. Wan, 2014, MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells by directly targeting PLD2, Mol Med Rep, 9, 503, 10.3892/mmr.2013.1814 · DOI
  121. Aigner, 2011, MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma, Cancer Res, 7, 5214, 10.1158/0008-5472.CAN-10-4645 · DOI
  122. Bader, 2012, miR-34 - a microRNA replacement therapy is headed to the clinic, Front Genet, 3, 120, 10.3389/fgene.2012.00120 · DOI
  123. Winkler, 2014, miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents, Future Med Chem, 6, 1967, 10.4155/fmc.14.116 · DOI
  124. Kocerha, 2019, The Potential for microRNA Therapeutics and Clinical Research, Front Genet, 1, 478, 10.3389/fgene.2019.00478 · DOI
  125. Lee, 2015, Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy, J Drug Target, 2, 360, 10.3109/1061186X.2014.1000336 · DOI
  126. Lee, 2017, Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model, J Drug Target, 2, 132, 10.1080/1061186X.2016.1207648 · DOI
  127. Kauppinen, 2013, Treatment of HCV infection by targeting microRNA, N Engl J Med, 36, 1685, 10.1056/NEJMoa1209026 · DOI
  128. Sharp, 2010, Emerging roles for natural microRNA sponges, Curr Biol, 2, R858, 10.1016/j.cub.2010.08.052 · DOI
  129. Han, 2014, A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cellsand, Oncol Rep, 3, 1573, 10.3892/or.2014.3012 · DOI
  130. Damgaard, 2013, Circular RNA and miR-7 in cancer, Cancer Res, 7, 5609, 10.1158/0008-5472.CAN-13-1568 · DOI
  131. Huang, 2015, delivery of miRNAs for cancer therapy: challenges and strategies, Adv Drug Deliv Rev, 8, 128, 10.1016/j.addr.2014.05.009 · DOI
  132. Wang, 2012, Construction of a recombinant lentivirus containing human microRNA-7-3 and its inhibitory effects on glioma proliferation, Neural Regen Res, 7, 2144, 10.3969/j.issn.1673-5374.2012.27.009 · DOI
  133. Krichevsky, 2017, Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b, Mol Ther, 2, 368, 10.1016/j.ymthe.2016.11.004 · DOI
  134. Mendell, 2009, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model, Cell, 13, 1005, 10.1016/j.cell.2009.04.021 · DOI · Paper page
  135. Mueller, 2014, Recombinant AAV as a platform for translating the therapeutic potential of RNA interference, Mol Ther, 2, 692, 10.1038/mt.2013.285 · DOI
  136. Yang, 2015, An overview of viral and nonviral delivery systems for microRNA, Int J Pharm Investig, 5, 179, 10.4103/2230-973X.167646 · DOI
  137. Kim, 2019, Recent advances in the development of gene delivery systems, Biomater Res, 2, 8, 10.1186/s40824-019-0156-z · DOI · Paper page
  138. Mondal, Sharma, Kulshreshtha. MicroRNA therapeutics in glioblastoma: Candidates and targeting strategies. In: Mallick, ed. AGO-Driven Non-Coding RNAs: Academic Press. 2019; pp. 261-92. · DOI
  139. Ridley, 2017, Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, Lancet Oncol, 1, 1386, 10.1016/S1470-2045(17)30621-6 · DOI
  140. Massoud, 2015, Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells, Mol Pharm, 1, 4509, 10.1021/acs.molpharmaceut.5b00694 · DOI
  141. Massoud, 2016, Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a “Personalized” Anti-microRNA Therapy, Mol Pharm, 1, 3164, 10.1021/acs.molpharmaceut.6b00388 · DOI
  142. Kim, 2006, Current status of polymeric gene delivery systems, Adv Drug Deliv Rev, 5, 467, 10.1016/j.addr.2006.03.007 · DOI
  143. Abounader, 2016, 370 Magnetic Resonance-Guided Focused Ultrasound Delivery of Polymeric Brain-Penetrating Nanoparticle MicroRNA Conjugates in Glioblastoma, Neurosurgery, 6, 210, 10.1227/01.neu.0000489858.08559.c8 · DOI
  144. Bozkır, 2018, Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells, Drug Dev Ind Pharm, 4, 306, 10.1080/03639045.2017.1391835 · DOI
  145. Bozkir, 2017, Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells, Drug Dev Ind Pharm, 4, 12, 10.1080/03639045.2016.1200069 · DOI
  146. Levine, 2017, Immune modulatory nanoparticle therapeutics for intracerebral glioma, Neuro Oncol, 1, 372, 10.1093/neuonc/now198 · DOI
  147. Geertsma, 2008, Particle size-dependent organ distribution of gold nanoparticles after intravenous administration, Biomaterials, 2, 1912, 10.1016/j.biomaterials.2007.12.037 · DOI
  148. Makino, 2008, Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size, Colloids Surf B Biointerfaces, 6, 274, 10.1016/j.colsurfb.2008.07.004 · DOI
  149. Dykman, 2011, Biodistribution and toxicity of engineered gold nanoparticles: a review ofandstudies, Chem Soc Rev, 4, 1647, 10.1039/c0cs00018c · DOI
  150. Park, 2014, Endocytosis and exocytosis of nanoparticles in mammalian cells, Int J Nanomedicine, 9, 51, 10.2147/IJN.S26592 · DOI
  151. Suresh, 2009, Size-Dependent Endocytosis of Nanoparticles, Adv Mater, 2, 419, 10.1002/adma.200801393 · DOI
  152. Kim, 2015, Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases, Nanomedicine, 1, 1603, 10.1016/j.nano.2015.04.015 · DOI
  153. Nicholson, 2008, Diffusion in brain extracellular space, Physiol Rev, 8, 1277, 10.1152/physrev.00027.2007 · DOI · Paper page
  154. Cognet, 2017, Single-nanotube tracking reveals the nanoscale organization of the extracellular space in the live brain, Nat Nanotechnol, 1, 238, 10.1038/nnano.2016.248 · DOI · Paper page
  155. Ferreira, 2018, A nanoformulation for the preferential accumulation in adult neurogenic niches, J Control Release, 28, 57, 10.1016/j.jconrel.2018.06.013 · DOI
  156. Broome, 2015, Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors, Nanoscale, 7, 1782, 10.1039/c4nr04853a · DOI
  157. Popovtzer, 2014, Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications, Nanoscale, 6, 2146, 10.1039/c3nr04878k · DOI
  158. Kreuter, 2011, Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB), J Drug Target, 1, 125, 10.3109/10611861003734001 · DOI · Paper page
  159. van Tellingen, 2014, Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101), PLoS One, 9, e82331, 10.1371/journal.pone.0082331 · DOI
  160. Hammarlund-Udenaes, 2013, Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study, Mol Pharm, 1, 1533, 10.1021/mp300272a · DOI
  161. Ensign, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv Drug Deliv Rev, 9, 28, 10.1016/j.addr.2015.09.012 · DOI · Paper page
  162. Arvanitis, 2021, Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles, Sci Adv, 7, eabf7390, 10.1126/sciadv.abf7390 · DOI
  163. Gilbert, 2016, MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints, Neuro Oncol, 1, 639, 10.1093/neuonc/nov292 · DOI
  164. Cartron, 2018, miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker, Mol Ther Nucleic Acids, 1, 642, 10.1016/j.omtn.2018.09.007 · DOI
  165. Liu, 2014, miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways, Int J Oncol, 4, 1571, 10.3892/ijo.2014.2322 · DOI

Cited by

Sorted by citations

See all 84

Metadata

Authors
Chen, M., Medarova, Z., & Moore, A.
Affiliations
  • Precision Health Program, Michigan State University, East Lansing, MI 48824, USA
  • Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2021-08-17
Volume
12
Issue
17
Pages
1707-1723
ISSN
1949-2553
DOI
10.18632/oncotarget.28039
PMC
PMC8378762
Cited by
84
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review